IBMP
IBMP is dedicated to delivering biotechnological solutions to improve health and social well-being through innovative research, development, and production of diagnostic kits and biotechnological products. The institute emphasizes integrity, ethics, and governance in its operations, aiming to be a reference in health innovation and technology in Brazil.
Industries
Nr. of Employees
medium (51-250)
Products
Molecular diagnostic kit portfolio (qPCR/RT-qPCR)
Range of nucleic acid detection kits using qPCR/RT-qPCR formatted for laboratory use; targets include arboviruses (Zika, dengue, chikungunya), febrile and neglected diseases (yellow fever, Chagas, malaria, rickettsiosis, trachoma), respiratory pathogens (Influenza A/B, SARS-CoV-2, RSV, adenovirus, rhinovirus/enterovirus), HPV high-risk genotypes and veterinary targets (rabies).
One-step RT-qPCR master mixes
Master mix reagent formulations for one-step RT-qPCR and PCR workflows provided as consumables for diagnostic testing and assay development.
Point-of-care antigen test (rapid immunoassay)
Portable antigen detection tests for rapid identification of respiratory pathogen antigens (example: SARS-CoV-2 antigen rapid test) intended for point-of-care or decentralized testing.
Kit IBMP
O Kit IBMP Biomol ZDC – Zika, Dengue e Chikungunya utiliza a técnica de transcrição reversa seguida de reação em cadeia da polimerase em tempo real (RT-qPCR) para detecção qualitativa do material genético do vírus Zika, dos sorotipos 1, 2, 3 e 4 do vírus da Dengue, e do vírus Chikungunya.
Kit IBMP Biomol Painel de Viroses Respiratórias
Solução molecular completa de alta performance para a detecção qualitativa e diferenciação simultânea de nove dos principais patógenos causadores de infecções respiratórias utilizando tecnologia RT-qPCR e qPCR.
Kit IBMP TR Dengue NS1
O Kit IBMP TR Dengue NS1 é um teste rápido baseado no método de imunocromatografia de fluxo lateral para a detecção qualitativa da proteína NS1 do vírus da Dengue em amostras de sangue total, soro ou plasma.
Molecular diagnostic kit portfolio (qPCR/RT-qPCR)
Range of nucleic acid detection kits using qPCR/RT-qPCR formatted for laboratory use; targets include arboviruses (Zika, dengue, chikungunya), febrile and neglected diseases (yellow fever, Chagas, malaria, rickettsiosis, trachoma), respiratory pathogens (Influenza A/B, SARS-CoV-2, RSV, adenovirus, rhinovirus/enterovirus), HPV high-risk genotypes and veterinary targets (rabies).
One-step RT-qPCR master mixes
Master mix reagent formulations for one-step RT-qPCR and PCR workflows provided as consumables for diagnostic testing and assay development.
Point-of-care antigen test (rapid immunoassay)
Portable antigen detection tests for rapid identification of respiratory pathogen antigens (example: SARS-CoV-2 antigen rapid test) intended for point-of-care or decentralized testing.
Kit IBMP
O Kit IBMP Biomol ZDC – Zika, Dengue e Chikungunya utiliza a técnica de transcrição reversa seguida de reação em cadeia da polimerase em tempo real (RT-qPCR) para detecção qualitativa do material genético do vírus Zika, dos sorotipos 1, 2, 3 e 4 do vírus da Dengue, e do vírus Chikungunya.
Kit IBMP Biomol Painel de Viroses Respiratórias
Solução molecular completa de alta performance para a detecção qualitativa e diferenciação simultânea de nove dos principais patógenos causadores de infecções respiratórias utilizando tecnologia RT-qPCR e qPCR.
Kit IBMP TR Dengue NS1
O Kit IBMP TR Dengue NS1 é um teste rápido baseado no método de imunocromatografia de fluxo lateral para a detecção qualitativa da proteína NS1 do vírus da Dengue em amostras de sangue total, soro ou plasma.
Services
Clinical laboratory testing service performing large-scale RT-PCR diagnostics for public health needs and surveillance.
Manufacturing and packaging of in vitro diagnostic kits, reagents and master mixes in a GMP/BPF-certified facility for third parties and internal brands.
Custom development and analytical validation of molecular and antigen assays, including multiplexing, internal control integration and stability testing.
NGS-based sequencing services and genomics research support for population studies, rare diseases and cancer research.
Clinical laboratory testing service performing large-scale RT-PCR diagnostics for public health needs and surveillance.
Manufacturing and packaging of in vitro diagnostic kits, reagents and master mixes in a GMP/BPF-certified facility for third parties and internal brands.
Custom development and analytical validation of molecular and antigen assays, including multiplexing, internal control integration and stability testing.
NGS-based sequencing services and genomics research support for population studies, rare diseases and cancer research.
Expertise Areas
- Molecular diagnostics development
- High-throughput RT-PCR testing and clinical diagnostics
- IVD manufacturing and GMP-compliant production
- Assay validation and analytical performance
Key Technologies
- Real-time PCR (qPCR/RT-qPCR)
- Multiplex PCR assays
- One-step RT-qPCR master mixes
- Next-generation sequencing (NGS)
News & Updates
The Minister of Health, Alexandre Padilha, visited IBMP and paid tribute to Marco Krieger.
The largest biofactory in the world for creating Wolbachia-infected Aedes aegypti mosquitoes was inaugurated in Curitiba.
The IBMP participated in a meeting with Philippe Duneton, the executive director of UNITAID, to discuss health innovation.
The diagnostic method developed by IBMP was chosen as the best work presented at an international symposium on health innovation.
The IBMP, in partnership with Fiocruz and Tecpar, has conducted over 2.5 million RT-PCR tests for COVID-19, supporting mass testing strategies.
IBMP's production plant received renewal of its Good Manufacturing Practices certification after successful audit by health authorities.
The Minister of Health, Alexandre Padilha, visited IBMP and paid tribute to Marco Krieger.
The largest biofactory in the world for creating Wolbachia-infected Aedes aegypti mosquitoes was inaugurated in Curitiba.
The IBMP participated in a meeting with Philippe Duneton, the executive director of UNITAID, to discuss health innovation.
The diagnostic method developed by IBMP was chosen as the best work presented at an international symposium on health innovation.
The IBMP, in partnership with Fiocruz and Tecpar, has conducted over 2.5 million RT-PCR tests for COVID-19, supporting mass testing strategies.
IBMP's production plant received renewal of its Good Manufacturing Practices certification after successful audit by health authorities.